Results thus far from monotherapy testing in the “Using Olaparib in Recurrent IDH-mutant Glioma” (OLAGLI) trial have demonstrated limited success with olaparib alone71, prompting interest in results from ongoing trials using PARP inhibitors in combination with agents such as TMZ (NCT03914742) or immunotherapy (NCT03991832)6. The gene discussed is IDH2; the disease is central nervous system cancer.